VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 1, 2026
Stock Comparison
Bristol-Myers Squibb Company vs Cintas Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisCintas Corporation
CTAS · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Cintas Corporation's moat claims, evidence, and risks.
View CTAS analysisComparison highlights
- Moat score gap: Cintas Corporation leads (63 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Cintas Corporation has 3 segments (77.1% in Uniform Rental and Facility Services).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Cintas Corporation has 5 across 2.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Cintas Corporation
Uniform Rental and Facility Services
B2B uniform rental and route-based facility services (entrance mats, restroom supplies, towels/mops, etc.)
North America (primarily United States; also Canada and Latin America)
Businesses (SMB to large enterprise) via local delivery routes and branches
Service operator / rental provider (route-based distribution and processing network)
77.1%
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
Cintas Corporation strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Cintas Corporation segments
Full profile >Uniform Rental and Facility Services
Competitive
First Aid and Safety Services
Competitive
All Other (Fire Protection Services and Uniform Direct Sale)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.